Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Application of the Syva EMIT and Abbott TDx Amphetamine Immunoassays to the Detection of 3,4-Methylenedioxymethamphetamine (MDMA) and 3,4-Methylenedioxyethamphetamine (MDEA) in Urine

Gary W. Kunsman, Joseph E. Manno, K.r. Cockerham, Barbara R. Manno

Journal of Analytical Toxicology May 1, 1990 DOI: 10.1093/jat/14.3.149 (opens in new tab) via OpenAlex

Summary

AI-generated from the abstract

MDMA and MDEA, hallucinogenic amphetamine analogs, are increasingly used recreationally, prompting evaluation of common urine drug tests. The Abbott TDx and Syva EMIT-d.a.u. amphetamine immunoassays were tested for cross-reactivity with MDMA- and MDEA-spiked urine samples. The Syva EMIT assay detected only the highest concentration (10.0 micrograms/mL) of both substances. The TDx assay showed cross-reactivity for MDMA ranging from 18% at high concentrations to 118% at low concentrations, and for MDEA from 12% to 47%. Precision for TDx was good, with coefficients of variation below 6% for MDMA. Negative EMIT but positive TDx results were confirmed by GC/MS.

Study at a glance

Characteristics Laboratory evaluation Peer reviewed
Population MDMA- and MDEA-spiked urine samples
Topics MDMA
Keywords Chemistry Amphetamine Urine Chromatography
Citations 34
Key finding The Abbott TDx amphetamine assay showed substantial cross-reactivity with MDMA (18-118%) and MDEA (12-47%), while the Syva EMIT-d.a.u. assay detected only the highest concentration of both substances.

Abstract

MDMA and MDEA are hallucinogenic analogs of amphetamine. The need for laboratory monitoring of these substances has developed as a result of their increased recreational use. Since the Abbott TDx and Syva EMIT-d.a.u. immunoassays are commonly used tests for urine monitoring of drugs-of-abuse, the amphetamine assay of each manufacturer was assessed to determine the degree of cross-reactivity with MDMA and MDEA. Cross-reactivity was evaluated using a series of MDMA- and MDEA-spiked urine samples. Testing was performed over a two-day period with 3 runs/day and each sample run in duplicate. The Syva EMIT d.a.u. amphetamine assay was positive only at the highest concentration standard (10.0 micrograms/mL) for both MDMA and MDEA. Consequently, no further testing was performed with this assay. Calibration curves were generated for the TDx runs and percent cross-reactivity determinations were made. Precision for the TDx data was evaluated based on within-day and between-day coefficients of variation (CV). CVs for MDMA runs were below 6% for within-day and below 5% for between-day runs. Values of CV for MDEA were below 16% for both within-day and between runs; CVs were less than 2.5% for positive values. Cross-reactivity for MDMA ranged from 18% (10.00 micrograms/mL) to 118% (0.15 microgram/mL). Cross-reactivity for the MDEA standards ranged from 12% (10.00 micrograms/mL) to 47% (0.15 micrograms/mL). The presence of MDMA and/or MDEA in samples resulting in a negative EMIT-d.a.u. test and a positive TDx test was confirmed by GC/MS analysis.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore topics

Comments

No comments yet.

Log in to comment